Nkarta Reports Third Quarter 2021 Financial Results and Business Update
November 10, 2021 16:01 ET
|
Nkarta, Inc.
Initial data expected in 1H 2022 from Phase 1 clinical trial of NKX101 in AML and MDSSuccessful dosing of NKX019 in patients with B cell malignancies; initial Phase 1 clinical trial data expected in...
Nkarta to Participate at Upcoming Investor Conferences
November 04, 2021 08:04 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs
October 07, 2021 16:01 ET
|
Nkarta, Inc.
First patients dosed in Phase 1 clinical trial evaluating NKX019 in CD19+ advanced B cell malignanciesInitial data from the NKX019 clinical trial expected in 2022Initial data from Phase 1 clinical...
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
October 01, 2021 08:08 ET
|
Nkarta, Inc.
Data support potential clinical applications of CRISPR/Cas9 genome engineering, CD70 chimeric antigen receptor (CAR) targeting, and donor selection algorithms in next generation NK cell development...
Nkarta to Participate at Upcoming Investor Conference
September 14, 2021 08:32 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
August 12, 2021 16:02 ET
|
Nkarta, Inc.
Initial data from NKX101 clinical trial expected by end of 2021NKX019 patient dosing expected to start in 2H 2021Collaboration with CRISPR Therapeutics to develop gene-edited cell therapiesNew lease...
Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters
July 14, 2021 07:00 ET
|
Nkarta, Inc.
88,000 square foot facility in South San Francisco will support scaled manufacturing of Nkarta’s engineered NK cell therapy candidates, and be home to company headquartersPlanned production expansion...
Nkarta to Present at Upcoming Investor Conference
June 16, 2021 07:00 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term
June 14, 2021 07:01 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Announces June 2021 Investor Conference Schedule
May 25, 2021 07:30 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today...